About Indoco Remedies Limited
Data last updated: 18 March 2026
Indoco Remedies Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 23 August 1947, the company has been in operation for over 79 years.
Registered with ROC Mumbai under CIN U85190MH1947PTC005913. Listed on BSE: 532612 and NSE: INDOCO.
Capital: an authorised share capital of ₹25 Cr and a paid-up capital of ₹18.46 Cr. It is led by directors including Vasudha Vasant Kamat and Anand Madhusudan Nadkarni.
Last AGM: 11 September 2025. Financial statements filed for year ended 31 March 2025. Office: Indoco House 166 Cst Roadvidyanagari Marg Kalina Santacruz East, Mumbai, Maharashtra, India – 400098.
As per the financials filed for FY 2025, the company reported a revenue of ₹1,670.37 Cr, a decline of 9% compared to the previous year.
The company has a workforce of approximately 6,460 employees as per the latest available data.
The company is associated with 2 brands - Anacipher Cro, Indoco Remedies. As per MCA filings, the company has open charges of ₹684.06 Cr and satisfied charges of ₹717.82 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website indoco.com.
-
Email**************
-
Telephone**************
-
Website**************
-
Social Media
-
Registered AddressIndoco House 166 Cst Roadvidyanagari Marg Kalina Santacruz East, Mumbai, Maharashtra, India – 400098
-
IndustryPharma, Drug Formulation & Development, API Manufacturers, Pharma Contract R&D
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Indoco Remedies Limited
Indoco Remedies Limited has one previous CIN (Corporate Identification Number): U85190MH1947PTC005913. The current CIN is L85190MH1947PLC005913, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L85190MH1947PLC005913 | Current |
| U85190MH1947PTC005913 | Previous |
Associated Brands with Indoco Remedies Limited
Indoco Remedies Limited operates two associated brands: AnaCipher CRO and Indoco Remedies. These brands represent Indoco Remedies Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Provides clinical research and bioequivalence studies for pharmaceutical partners. | anaciphercro.com | |
| APIs manufacturing and formulation services are provided in therapeutic segments. | indoco.com |
Competitors & Alternatives of Indoco Remedies Limited
Brands and companies operating in the same space as Indoco Remedies Limited include Concord Biotech, BDR Pharmaceuticals Internationals, Almac Group and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Concord Biotech
|
APIs and enzymes are manufactured through fermentation by the CDMO. | Ahmedabad, India, India | 2000 |
BDR Pharmaceuticals Internationals
|
APIs and finished products are developed and manufactured. | Mumbai, India, India | 2003 |
Almac Group
|
Integrated CDMO services for biopharma R&D and manufacturing are offered. | Craigavon, United Kingdom, United Kingdom | 2001 |
Alderley Analytical
|
Bioanalytical assays for drug development are developed and validated. | Stockport, United Kingdom, United Kingdom | 2013 |
BioAgilytix
|
Large-molecule bioanalysis is provided for biologics and biosimilars development. | Durham, United States, United States | 2008 |
Lightcast Discovery
|
Advanced single-cell analysis solutions are provided for biotechnology research. | Cambridge, United Kingdom, United Kingdom | 2019 |
Pharmaceutics International
|
Pharmaceutical dosage forms are manufactured by this CDMO. | Hunt Valley, United States, United States | 1994 |
Aurobindo Pharma
|
Generic biocatalytic solutions are provided for pharmaceutical applications. | Hyderabad, India, India | 1986 |
Seqens
|
Contract manufacturing services for small molecules and peptides are provided. | Ecully, France, France | 2003 |
Asymchem
|
APIs and peptides are developed and manufactured by Asymchem. | Morrisville, United States, United States | 1995 |
Business Activity of Indoco Remedies Limited
Indoco Remedies Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Board of Directors of Indoco Remedies Limited
Indoco Remedies Limited is currently managed by 10 directors, with 24 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Vasudha Vasant Kamat | Director | 27 Mar 2020 | 6 Years 3 Months | Current |
| Anand Madhusudan Nadkarni | Director | 28 May 2014 | 12 Years 1 Months | Current |
| Ajay Prasan Mulgaokar | Director | 01 Apr 2024 | 2 Years 3 Months | Current |
|
Satish Madhav Shenoy
Also directs:
Kataline Limited
|
Director | 01 Apr 2024 | 2 Years 3 Months | Current |
| Abhijit Yashawant Gore | Director | 03 Oct 2020 | 5 Years 9 Months | Current |
| Sundeep Vasant Bambolkar | Managing Director | 27 Mar 2004 | 22 Years 3 Months | Current |
Financials of Indoco Remedies Limited FY 2025 filings available
Indoco Remedies Limited reported revenue of ₹1,670.37 Cr (down 9% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Charges & Borrowings of Indoco Remedies Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Apr 2025 | Hdfc Bank Limited | ₹244 Cr | Open |
| 27 Feb 2025 | Others | ₹50 Cr | Open |
| 27 Jun 2024 | Hdfc Bank Limited | ₹42 Cr | Open |
| 30 May 2024 | Hdfc Bank Limited | ₹28 Cr | Open |
| 14 Dec 2023 | Hdfc Bank Limited | ₹50 Cr | Open |
Total charge records: 80 View all charges
Employees and EPFO Compliance at Indoco Remedies Limited
View historical data on people associated with Indoco Remedies Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Indoco Remedies Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Indoco Remedies Limited
GSTIN & GST Filing Data of Indoco Remedies Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Indoco Remedies Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Indoco Remedies Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Indoco Remedies Limited
MSME Payment Delays by Indoco Remedies Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Indoco Remedies Limited
Subsidiaries & Group Companies of Indoco Remedies Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Indoco Remedies Limited with ownership details.
MCA Filings & Documents of Indoco Remedies Limited
MCA Filings & Documents of Indoco Remedies Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Indoco Remedies Limited
Recent News on Indoco Remedies Limited
Frequently Asked Questions about Indoco Remedies Limited
Indoco Remedies Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 23 August 1947 (79+ years old) and is registered under CIN L85190MH1947PLC005913. Listed on BSE: 532612 and NSE: INDOCO. The company has 6,460 employees.
Indoco Remedies Limited reported revenue of ₹1,670.37 Cr for FY 2025 (down 9.00% YoY).
The current directors of Indoco Remedies Limited are:
- Vasudha Vasant Kamat
- Anand Madhusudan Nadkarni
- Ajay Prasan Mulgaokar
- Pramod Ramchandra Ghorpade
- Satish Madhav Shenoy
- Abhijit Yashawant Gore
- Sundeep Vasant Bambolkar
- Aditi Milind Panandikar
- Suresh Govind Kare
- Ramanathan Hariharan
The primary industry of Indoco Remedies Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Indoco Remedies Limited is listed on both BSE (code: 532612) and NSE (symbol: INDOCO).
Indoco Remedies Limited can be reached at the registered office: Indoco House 166 Cst Roadvidyanagari Marg Kalina Santacruz East, Mumbai, Maharashtra, India – 400098, or through the website indoco.com.